Steris (NYSE:STE) issued an update on its FY19 earnings guidance on Tuesday morning. The company provided EPS guidance of $4.74-4.84 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.70. Steris also updated its FY 2019 guidance to $4.74-4.84 EPS.
STE stock traded up $1.20 during trading on Tuesday, reaching $113.24. 3,963 shares of the stock were exchanged, compared to its average volume of 392,523. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.65 and a quick ratio of 2.02. Steris has a 1 year low of $82.88 and a 1 year high of $117.48. The company has a market capitalization of $9.46 billion, a PE ratio of 27.29 and a beta of 1.03.
Steris (NYSE:STE) last issued its earnings results on Wednesday, August 8th. The medical equipment provider reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.01. Steris had a net margin of 11.42% and a return on equity of 11.80%. The company had revenue of $638.76 million for the quarter, compared to the consensus estimate of $638.63 million. During the same period in the previous year, the firm earned $0.85 earnings per share. Steris’s quarterly revenue was up 5.1% compared to the same quarter last year. Sell-side analysts forecast that Steris will post 4.71 EPS for the current year.
STE has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Steris from a sell rating to a hold rating in a research note on Monday, September 3rd. JMP Securities lifted their target price on shares of Steris from $113.00 to $125.00 and gave the stock a market outperform rating in a research note on Thursday, August 9th. Stephens reaffirmed a buy rating and set a $125.00 target price on shares of Steris in a research note on Thursday, August 9th. Finally, KeyCorp boosted their price target on shares of Steris from $115.00 to $120.00 and gave the company an overweight rating in a research note on Thursday, August 9th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Steris presently has a consensus rating of Buy and a consensus target price of $100.86.
In other news, VP Karen L. Burton sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $114.39, for a total value of $148,707.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.38% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Macon Daily and is owned by of Macon Daily. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://macondaily.com/2018/11/06/steris-ste-issues-fy19-earnings-guidance.html.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Further Reading: How is a Moving Average Calculated?
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.